Thursday, April 30, 2026
ISSN 2765-8767
  • Survey
  • Podcast
  • Write for Us
  • My Account
  • Log In
Daily Remedy
  • Home
  • Articles
  • Podcasts
    How NADAC, WAC, and ASP Shape Drug Costs

    How NADAC, WAC, and ASP Shape Drug Costs

    April 20, 2026
    The Hidden Costs Employers Don’t See in Traditional Health Plans

    The Hidden Costs Employers Don’t See in Traditional Health Plans

    March 22, 2026
    The Impact of COVID-19 on Patient Trust

    The Impact of COVID-19 on Patient Trust

    March 3, 2026
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
  • Surveys

    Surveys

    Public Perception of Peptide Regulation and Compounding Practices

    Public Perception of Peptide Regulation and Compounding Practices

    April 19, 2026
    Understanding of Clinical Evidence in Peptide and Hormone Use

    Understanding of Clinical Evidence in Peptide and Hormone Use

    March 30, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
  • Home
  • Articles
  • Podcasts
    How NADAC, WAC, and ASP Shape Drug Costs

    How NADAC, WAC, and ASP Shape Drug Costs

    April 20, 2026
    The Hidden Costs Employers Don’t See in Traditional Health Plans

    The Hidden Costs Employers Don’t See in Traditional Health Plans

    March 22, 2026
    The Impact of COVID-19 on Patient Trust

    The Impact of COVID-19 on Patient Trust

    March 3, 2026
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
  • Surveys

    Surveys

    Public Perception of Peptide Regulation and Compounding Practices

    Public Perception of Peptide Regulation and Compounding Practices

    April 19, 2026
    Understanding of Clinical Evidence in Peptide and Hormone Use

    Understanding of Clinical Evidence in Peptide and Hormone Use

    March 30, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
Daily Remedy
No Result
View All Result
Home Trends

Is Europe a Leading Indicator for COVID-19?

Daily Remedy by Daily Remedy
November 28, 2021
in Trends
0
Is Europe a Leading Indicator for COVID-19?

Data is many things. But above all, it is counterintuitive.

The more we add to it, the more complex it becomes. The more complex it becomes, the greater the probability of error.

Yet we cannot curb this tendency of adding more variables to data – almost like we are compelled to believe the more variables we study in a given data set, the more accurate it becomes.

Like most counterintuitive concepts in healthcare, our intuition fails us, leading down a road of false equivalencies and misplaced attributions.

This seems to be where we are at currently, heading into the second pandemic winter and anticipating another COVID-19 surge in cases. After all, we see cases rising all across Europe and a new variant, Omicron, seems to have captured the media’s attention for the moment.

Germany, with 68% percent of the population fully vaccinated and known for adhering steadfastly to mask mandates and social distancing protocols, is experiencing its highest peak in COVID-19 cases since the pandemic started.

Norway, with 86% percent of the population 18 and older vaccinated, is also bracing for an uptick in COVID-19 cases. “Based on an overall assessment, we believe it is likely that we will get a wave [of COVID-19 infections] during the winter,” said Miss Camilla Stoltenberg, head of the Norwegian Institute of Public Health.

Throughout Europe, from the United Kingdom to Germany, COVID-19 cases are rising, and policy experts across the world are bracing for the worst – particularly in the United States.

Growing outbreaks in the Midwest and Northeast are responsible for the recent increase in COVID-19 cases in the United States, which is coming after weeks of regional surges in the Mountain West where some hospitals are still grappling with hospital capacity constraints.

And of course, whenever COVID-19 cases surge, people look for things to blame. Some believe the rising cases in highly vaccinated countries are proof the vaccines are ineffective. Some are even blaming the type of vaccine.

The CEO of AstraZeneca, Pascal Soriot, blames the recent surge on the mRNA vaccines produced by Moderna and Pfizer-BioNTech. Soriot said, “it’s really interesting when you look at the UK. There was a big peak of infections but not so many hospitalizations relative to Europe. In the UK [the Oxford/AstraZeneca] vaccine was used to vaccinate older people whereas in [other parts of] Europe people thought initially [our] vaccine doesn’t work in older people.”

But blaming any one attribute or cause is nothing more than a logical failure, known among behavioral economists as attribution error. At the end of the day, we do not have a simple explanation for why COVID-19 cases are rising, as scary as that may appear. To blame any one thing – whether it is vaccines, mask mandates, or economic restrictions – overlooks the massive uncertainty in the data that we have yet to fully grasp.

There is more we do not know than know – even this late into the pandemic. But we continue to reach for convenient solutions.

In the United States, these solutions usually come in the form of political grandstanding over hot-button cultural issues. Those who support vaccinations will blame parts of the country with low vaccination rates, just like those who are against vaccinations will claim that vaccines are not effective.

The arguments are circular because the data remains inconclusive – so we apply value judgments to parts of the data that corroborate with what we already believe.

Ultimately, the rise in COVID-19 may be nothing more than broad endemic trend, like seasonal influenza. We may just have to learn to live with COVID-19. And cases along with new variants will appear with certain seasonality like influenza, or any other viral upper respiratory tract infection.

Vaccines will help those who are at risk and reduce the burden of treatment in hospital systems. But they will not stop people from getting infected.

Mask mandates and economic restrictions will reduce the transmission of viruses and prevent massive surges in COVID-19 that have overwhelmed hospitals in the past. But they will not stop the spread of the virus completely.

It is impossible to say how effective any one of these measures can be in isolation because their overall effect in curbing COVID-19 is fundamentally interdependent. Just like the rise in COVID-19 cases has no one cause or attributable factor.

Both the rise in cases and the mitigating treatment options operate within a broader system, influencing and impacting each other in a complex, coordinated dance that we do not yet understood.

As far as we know, the COVID-19 pandemic might have already transitioned into seasonal endemic infections, producing corona virus variants the same way other airborne viruses mutate. And we may not recognize this transition until months or years later.

We might not ever recognize it. We still do not have a full understanding of influenza after living with it for a century since the Spanish Flu. The only difference between influenza and COVID-19 is how we conceptualize it.

We accept seasonal rises in influenza and prepare for it accordingly. But when it comes to COVID-19, we cannot curb this tendency to analyze it ad nauseam, looking for something – really anything – to blame.

Europe may be a leading indicator, but the innumerable variables differentiating the United States from European countries begs the question of whether any perceived similarity is a real trend or just a convenient aberration in the numbers.

Instead of trying to predict it, to find blame out of it, we should learn to accept it. Accept that COVID-19 will be a seasonal endemic infection more severe than traditional influenza infections for at least another four to five years, at which time global herd immunity will have acclimated to the various COVID-19 variants.

And then we will live with endemic COVID variants like we live with annual influenza variants. We will try to predict the likely variants and formulate annual vaccines to maximize effectiveness – and over time we will be more right than wrong, just like we are with influenza vaccines.

Time, more than anything else, is the best indicator of how the pandemic will play out.

And eventually, we will learn to live with COVID-19 and accept it as part of our everyday lives, like we do all other airborne viruses swirling about.

ShareTweet
Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Videos

summary

An in-depth exploration of drug pricing, including key databases like NADAC, WAC, and ASP, and how they influence the pharmaceutical supply chain, policy, and patient advocacy. The episode also introduces MedPricer's innovative pricing intelligence platform, offering valuable insights for healthcare professionals, policymakers, and patients.

Chapters

00:00 Understanding Drug Pricing Dynamics
03:52 Exploring the Drug Pricing Database
10:07 Patient Advocacy and Drug Pricing
13:56 Market Intelligence in Drug Pricing
How NADAC, WAC, and ASP Shape Drug CostsDaily Remedy
YouTube Video X-Tfwy7XKEg
Subscribe

Policy Shift in Peptide Regulation

Clinical Reads

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

by Daily Remedy
April 19, 2026
0

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!

Twitter Updates

Tweets by TheDailyRemedy

Popular

  • Employer-Sponsored Insurance Is Breaking Down. Price Data Tells You Where It’s Happening First.

    Employer-Sponsored Insurance Is Breaking Down. Price Data Tells You Where It’s Happening First.

    0 shares
    Share 0 Tweet 0
  • Chronic Care Toolbox

    1 shares
    Share 0 Tweet 0
  • The Importance of Access Control in the Workplace

    0 shares
    Share 0 Tweet 0
  • Drug Pricing Transparency in an Era of Political Polarization: What MedPricer’s Data Reveals About a Contested Policy Landscape

    0 shares
    Share 0 Tweet 0
  • State Regulators and the Federal Data Gap: How MedPricer Fills What CMS Leaves Incomplete

    0 shares
    Share 0 Tweet 0
  • 628 Followers

Daily Remedy

Daily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.

Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.

Important Links

  • Support Us
  • About Us
  • Contact us
  • Privacy Policy
  • Terms and Conditions

Join Our Newsletter!

  • Survey
  • Podcast
  • About Us
  • Contact us

© 2026 Daily Remedy

No Result
View All Result
  • Home
  • Articles
  • Podcasts
  • Surveys
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner

© 2026 Daily Remedy